Literature DB >> 2894223

Cardiac effects of beta-adrenoceptor blockade with intrinsic sympathomimetic activity during submaximal exercise.

P A Ades1.   

Abstract

1. beta-adrenoceptor blocking agents with intrinsic sympathomimetic activity (ISA) are characterized by lesser depression of cardiac performance during low levels of sympathetic stimulation than beta-adrenoceptor blocking agents lacking ISA. Studies of the effects of ISA on cardiac output and on the determinants of myocardial oxygen demand during submaximal exercise are described and distinct differences between beta-adrenoceptor antagonists with and without ISA emerge. 2. At doses which produce similar effects on maximal exercise heart rate, and resting and exercise systolic blood pressure, pindolol, a beta-adrenoceptor blocking agent with substantial ISA, allows a higher submaximal exercise cardiac output and submaximal heart rate X systolic blood pressure product than does propranolol, a beta-adrenoceptor antagonist without ISA. 3. These findings may have clinical relevance in specific groups of patients such as those with arterial hypertension, where the preservation of cardiac function may allow for a more physiologic exercise response. Implications in patients with coronary artery disease and chronic heart failure await further study.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2894223      PMCID: PMC1386205          DOI: 10.1111/j.1365-2125.1987.tb03265.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Experience with pindolol, a betareceptor blocker, in the treatment of hypertension.

Authors:  J H Atterhög; H Dunér; B Pernow
Journal:  Am J Med       Date:  1976-05-31       Impact factor: 4.965

2.  Haemodynamic effects of oxprenolol in hypertensive patients.

Authors:  P A Majid; B Sharma; C Saxton; J B Stoker; S H Taylor
Journal:  Postgrad Med J       Date:  1970-11       Impact factor: 2.401

3.  Effects of beta-adrenergic blockade on the cardiac response to maximal and submaximal exercise in man.

Authors:  S Epstein; B F Robinson; R L Kahler; E Braunwald
Journal:  J Clin Invest       Date:  1965-11       Impact factor: 14.808

4.  Attenuation of exercise conditioning by low dose beta-adrenergic receptor blockade.

Authors:  R C Marsh; W R Hiatt; H L Brammell; L D Horwitz
Journal:  J Am Coll Cardiol       Date:  1983-09       Impact factor: 24.094

5.  How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism.

Authors:  A J Man in 't Veld; M A Schalekamp
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

6.  Cardiorespiratory alterations consequent to endurance exercise training during chronic beta-adrenergic blockade with atenolol and propranolol.

Authors:  J H Wilmore; G A Ewy; B J Freund; A A Hartzell; S M Jilka; M J Joyner; C A Todd; S M Kinzer; E B Pepin
Journal:  Am J Cardiol       Date:  1985-04-26       Impact factor: 2.778

7.  Attenuation of exercise conditioning by beta-adrenergic blockade.

Authors:  D L Sable; H L Brammell; M W Sheehan; A S Nies; J Gerber; L D Horwitz
Journal:  Circulation       Date:  1982-04       Impact factor: 29.690

Review 8.  Pharmacodynamic properties of beta-adrenergic receptor blocking drugs in man.

Authors:  D G Gibson
Journal:  Drugs       Date:  1974       Impact factor: 9.546

9.  Mode of action of beta-adrenoceptor blocking agents in hypertension. A comparison between metoprolol and pindolol with special reference to peripheral vascular effects.

Authors:  A Svensson; T Gudbrandsson; R Sivertsson; L Hansson
Journal:  Acta Med Scand Suppl       Date:  1982

10.  Beneficial effects of long-term beta-blockade in congestive cardiomyopathy.

Authors:  K Swedberg; A Hjalmarson; F Waagstein; I Wallentin
Journal:  Br Heart J       Date:  1980-08
View more
  1 in total

1.  Enalapril versus combined enalapril and nadolol treatment: effects on blood pressure, heart rate, humoral variables, and plasma potassium at rest and during exercise in hypertensive patients.

Authors:  P A Sullivan; B Daly; R O'Connor
Journal:  Cardiovasc Drugs Ther       Date:  1992-06       Impact factor: 3.727

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.